Orexigen Therapeutics, Inc. ( OREX ) entered into a commercial supply agreement with Sanofi ( SNY ) for its obesity drug, Contrave, EMA approval at the door and CONTRAVE will be the ONLY EMA approved drug in EUROPE.
GOLD BULLION rose to 6-week highs above $1250 per ounce in London's wholesale market Tuesday as European equities shrugged off poor data from China and S&P futures pointed higher on Wall Street.
We also know that Thomas Eric Duncan, the Liberian man who was the first person to be diagnosed with Ebola on U.S. soil, and Ashoka Mukpo, the NBC cameraman flown back to Nebraska for treatment, received Chimerix's experimental antiviral drug brincidofovir. Mukpo is said to be recovering; Duncan passed away Oct. 8.
Read MoreWhy we haven't cured Ebola yet
It's important to remember that none of these drugs were used in controlled clinical trial settings for Ebola, and it's difficult to take anything away about their efficacy, or lack thereof, from these circumstances. Each patient had a unique experience, also received supportive care and in some cases, received donated blood from Ebola survivors.
So too, will the experiences of the three other patients, whose treatment hasn't been disclosed, be unique.
Seeing some activity in hepatitis C, an RNA virus, prompted BioCryst scientists to pursue tests of BCX4430 against other RNA viruses. That’s what led the company to filoviruses, the family of viruses that cause viral hemorrhagic fevers. Both Ebola and Marburg are filoviruses.
National Institute of Allergy and Infectious Diseases (NIAID) has exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2.0 million increase to the existing development contract.
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
Travis K. Warren, Jay Wells, Rekha G. Panchal, Kelly S. Stuthman, Nicole L. Garza, Sean A. Van Tongeren, Lian #$%$, Cary J. Retterer, Brett P. Eaton, Gianluca Pegoraro, Shelley Honnold, Shanta Bantia, Pravin Kotian, Xilin Chen, Brian R. Taubenheim, Lisa S. Welch, Dena M. Minning, Yarlagadda S. Babu
I like this article as this has TRUE information and not according to situation like todays date. If this article was published yesterday BCRX would have been $50.